Status:
WITHDRAWN
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
Lead Sponsor:
Prexton Therapeutics
Conditions:
Parkinson Disease
Eligibility:
All Genders
35-85 years
Phase:
PHASE2
Brief Summary
This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Comp...
Eligibility Criteria
Inclusion
- Between 35 and 85 years of age, inclusive, at the time of signing informed consent
- Diagnosed after the age of 30 years with idiopathic PD
- A documented medical history of idiopathic PD for at least 3 years
- Disease severity of 2 to 4 on the modified Hoehn and Yahr scale when in the OFF state
- Been treated with a stable regimen of levodopa-containing therapy
- Subjects must be receiving at least 3 doses per day of levodopa-containing therapy, and must be on a stable dose for at least 2 weeks for immediate-release levodopa or at least 6 weeks for prolonged-release levodopa preparations prior to the first screening visit
- Experienced LID over a period of at least 3 months prior to randomization
- If needed, in the opinion of the investigator, subjects must have a caregiver
- Female subjects will be women of non-childbearing potential
Exclusion
- Patient is currently participating in or has participated in another study in the last 3 months
- Subjects with atypical, secondary, or drug-induced Parkinsonism
- Subjects with a history of dyskinesia that was exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic without peak-dose dyskinesia
- Subjects with a MoCA score of \<25
- Subjects who have, or who had a history of, any clinically significant hepatic or gallbladder disorder, as determined by the investigator
- Subjects who have dementia, currently active psychosis, or hallucinations.
- Suicide attempt within 1 year prior to the first screening visit, or severe suicidal ideation within 6 months prior to the first screening visit
- Subject has a current diagnosis of epilepsy,
- Any known contraindication to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma
- Carcinoma or successfully treated squamous cell carcinoma of the skin and no sing of disease recurrence for at least 5 years
- Subjects who have had a clinically significant illness within 4 weeks before the first dose, as determined by the investigator
- Subjects with scheduled surgeries/hospitalizations during the study period
- Any advanced, severe, or unstable disease (other than PD) that may interfere with the primary and secondary study outcome evaluations
- Subjects who have undergone prior neurosurgical operation for PD,
- Subjects currently taking (or expected to be administered during the course of the study) any of the prohibited medications (amantadine, safinamide, dopamine-antagonists).
Key Trial Info
Start Date :
January 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03331848
Start Date
January 15 2018
End Date
February 1 2019
Last Update
March 22 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.